Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

108.17
+2.051.93%
Pre-market: 109.271.10+1.01%04:00 EDT
Volume:1.15M
Turnover:124.20M
Market Cap:12.28B
PE:31.98
High:108.49
Open:106.20
Low:105.91
Close:106.12
52wk High:108.49
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:0.58
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.53
PE(LYR):42.25

Loading ...

Halozyme director Bernadette Connaughton sells 1,625 shares worth $107,591.25

Reuters
·
Jun 03

Averin Capital Acquisition names Akiko Moni Miyashita to board

Reuters
·
May 30

Potential End to Current Market Rally Hinges on Strait of Hormuz, Says Sinolink Securities

Stock News
·
May 24

J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)

TIPRANKS
·
May 20

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Halozyme Therapeutics Inc : JP Morgan Resumes Coverage With Neutral Rating; Price Target $70

THOMSON REUTERS
·
May 20

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

GlobeNewswire
·
May 19

These 10 'HALO' stocks protect your portfolio from the AI bubble

Dow Jones
·
May 16

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)

TIPRANKS
·
May 14

Stock Track | Halozyme Therapeutics Plummets 5.03% Intraday Amid Margin Compression and Earnings Volatility Concerns

Stock Track
·
May 14

Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative

Simply Wall St.
·
May 13

Halozyme Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 13

Halozyme price target lowered to $93 from $96 at Morgan Stanley

TIPRANKS
·
May 13

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

MT Newswires Live
·
May 12

These 10 'HALO' stocks protect your portfolio from the AI bubble

Dow Jones
·
May 12

Stock Track | Halozyme Therapeutics Soars 7.71% Intraday on Strong Q1 Earnings Beat and Analyst Optimism

Stock Track
·
May 12

Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating

MT Newswires Live
·
May 12

Analysts’ Top Healthcare Picks: Halozyme (HALO), MindWalk Holdings (HYFT)

TIPRANKS
·
May 12

Halozyme (HALO) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 12

Stock Track | Halozyme Therapeutics Soars 6.91% in Pre-Market on Q1 Earnings Beat

Stock Track
·
May 12